Ar­ray joins Pfiz­er on an­ti-can­cer com­bos, the lat­est in a string of binime­tinib com­bi­na­tions

Pfiz­er $PFE has struck a deal with Boul­der-based Ar­ray Bio­Phar­ma $AR­RY to fund clin­i­cal tri­als in­volv­ing sev­er­al an­ti-can­cer com­bi­na­tions from both drug­mak­ers.

The plan is to test the po­ten­tial ben­e­fits of com­bin­ing mol­e­c­u­lar­ly tar­get­ed ther­a­pies with im­munother­a­pies. The com­pa­nies will start with com­bin­ing Ar­ray’s MEK in­hibitor binime­tinib with Pfiz­er’s in­ves­ti­ga­tion­al PARP in­hibitor ta­la­zoparib, and avelum­ab, a hu­man an­ti-PD-L1 IgG1 mon­o­clon­al an­ti­body.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER